Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.

被引：0
|
作者：
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma Catherine
Opalinska, Joanna
机构：
[1] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Dept Med, New York, NY USA
[2] Univ Rochester, Rochester, NY USA
[3] GlaxoSmithKline, London, England
[4] GlaxoSmithKline, Boston, MA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline, Upper Providence, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8073
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Suvannasankha, A.
    Prawitz, T.
    Kapetanakis, V.
    Sarri, G.
    Hughes, R.
    Wang, F.
    Hogea, C.
    Ferrante, S. Allen
    Gutierrez, B.
    Gorsh, B.
    Willson, J.
    Popat, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S654 - S654
  • [42] A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Gabor, Mikala
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S505
  • [43] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [44] An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, H. Miles
    Schenkel, Brad
    Mileshkin, Linda
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 46 - 55
  • [45] Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
    Khwaja, Jahanzaib
    Bomsztyk, Joshua
    Atta, Maria
    Bygrave, Ceri
    Forbes, Adam
    Durairaj, Senthil
    Fernandes, Savio
    Taylor, James
    Paterson, Pamela
    Brearton, Gillian
    Crawley, Charles
    Sheehy, Oonagh
    Brown, Rachel
    Soutar, Richard
    Garg, Mamta
    Rydzewski, Andrzej
    Jamroziak, Krzysztof
    Mahmood, Shameem
    Wechalekar, Ashutosh D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (05) : 1811 - 1815
  • [46] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [47] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Nooka, Ajay
    Stockerl-Goldstein, Keith
    Abonour, Rafat
    Ramaekers, Ryan
    Khot, Amit
    Forbes, Adam
    Lee, Cindy
    Augustson, Bradley
    Spencer, Andrew
    Mateos, Maria-Victoria
    Chopra, Bikramjit
    Rogers, Rachel
    Smith, Deborah A.
    Davidge, Jacqueline
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Quach, Hang
    BLOOD, 2020, 136
  • [48] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [50] Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    Prince, H. Miles
    Adena, Michael
    Smith, Dell Kingsford
    Hertel, Judy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 93 - 99
12345